Corvus Pharmaceuticals Inc
CRVS6.120USD
+0.330+5.70%
Close 09/18, 16:00（ET）Quotes delayed by 15 min
456.03MMarket Cap
LossP/E TTM
More Details of Corvus Pharmaceuticals Inc Company
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of ITK inhibition as a new approach to immunotherapy for a range of cancer and immune diseases. Its lead product candidate is soquelitinib, a selective, covalent inhibitor of ITK (interleukin 2 inducible T cell kinase) and is in a multi-center Phase 1/1b clinical trial in patients with various recurrent, malignant T cell lymphomas. Soquelitinib is designed to inhibit the proliferation of certain malignant T cells. Its second product candidate, ciforadenant, is an oral, small molecule antagonist of the A2A receptor for adenosine designed to disable a tumor’s ability to subvert attack by the immune system by blocking the binding of immunosuppressive adenosine in the tumor microenvironment to the A2A receptor. The Company’s third product candidate is mupadolimab, a humanized monoclonal antibody that is designed to react with a specific site on CD73.
Company Info
Ticker SymbolCRVS
Company nameCorvus Pharmaceuticals Inc
IPO dateMar 23, 2016
CEODr. Richard A. Miller, M.D.
Number of employees31
Security typeOrdinary Share
Fiscal year-endMar 23
Address863 Mitten Rd Ste 102
CityBURLINGAME
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code94010-1311
Phone16509004520
Websitehttps://www.corvuspharma.com/
Ticker SymbolCRVS
IPO dateMar 23, 2016
CEODr. Richard A. Miller, M.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Richard A. Miller, M.D.
Dr. Richard A. Miller, M.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
2.32M
+31.66%
Mr. Leiv Lea
Mr. Leiv Lea
Chief Financial Officer
Chief Financial Officer
282.44K
--
Dr. Linda S. Grais, M.D., J.D.
Dr. Linda S. Grais, M.D., J.D.
Independent Director
Independent Director
10.00K
--
Mr. Scott W. Morrison, CPA
Mr. Scott W. Morrison, CPA
Independent Director
Independent Director
--
--
Mr. Jeffrey S. Arcara
Mr. Jeffrey S. Arcara
Senior Vice President, Chief Business Officer
Senior Vice President, Chief Business Officer
--
--
Dr. Peter A. Thompson, M.D.
Dr. Peter A. Thompson, M.D.
Independent Director
Independent Director
--
--
Mr. Ian T. Clark
Mr. Ian T. Clark
Independent Director
Independent Director
--
--
Dr. William B. Jones, Ph.D.
Dr. William B. Jones, Ph.D.
Senior Vice President - Pharmaceutical Development
Senior Vice President - Pharmaceutical Development
--
--
Mr. Richard van Den Broek
Mr. Richard van Den Broek
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Richard A. Miller, M.D.
Dr. Richard A. Miller, M.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
2.32M
+31.66%
Mr. Leiv Lea
Mr. Leiv Lea
Chief Financial Officer
Chief Financial Officer
282.44K
--
Dr. Linda S. Grais, M.D., J.D.
Dr. Linda S. Grais, M.D., J.D.
Independent Director
Independent Director
10.00K
--
Mr. Scott W. Morrison, CPA
Mr. Scott W. Morrison, CPA
Independent Director
Independent Director
--
--
Mr. Jeffrey S. Arcara
Mr. Jeffrey S. Arcara
Senior Vice President, Chief Business Officer
Senior Vice President, Chief Business Officer
--
--
Dr. Peter A. Thompson, M.D.
Dr. Peter A. Thompson, M.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Tue, Aug 19
Updated: Tue, Aug 19
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
OrbiMed Advisors, LLC
9.62%
Point72 Asset Management, L.P.
9.45%
BlackRock Institutional Trust Company, N.A.
4.85%
The Vanguard Group, Inc.
4.40%
Adams Street Partners, LLC
4.40%
Other
67.28%
Shareholders
Shareholders
Proportion
OrbiMed Advisors, LLC
9.62%
Point72 Asset Management, L.P.
9.45%
BlackRock Institutional Trust Company, N.A.
4.85%
The Vanguard Group, Inc.
4.40%
Adams Street Partners, LLC
4.40%
Other
67.28%
Shareholder Types
Shareholders
Proportion
Private Equity
18.27%
Investment Advisor
13.70%
Hedge Fund
11.25%
Investment Advisor/Hedge Fund
8.69%
Individual Investor
3.96%
Venture Capital
3.00%
Research Firm
1.01%
Pension Fund
0.20%
Bank and Trust
0.09%
Other
39.83%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
154
41.04M
53.29%
-590.66K
2025Q1
158
41.01M
55.15%
-1.27M
2024Q4
137
42.04M
65.42%
+8.08M
2024Q3
112
32.95M
52.86%
+765.53K
2024Q2
108
30.52M
48.98%
-5.02M
2024Q1
116
20.23M
41.14%
-8.66M
2023Q4
119
21.51M
43.96%
-7.95M
2023Q3
129
21.52M
44.20%
-7.79M
2023Q2
132
21.81M
46.84%
-8.41M
2023Q1
121
23.10M
49.61%
-7.89M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
OrbiMed Advisors, LLC
7.17M
9.29%
+221.35K
+3.19%
Jun 27, 2025
Point72 Asset Management, L.P.
2.79M
3.61%
-242.38K
-8.00%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
965.04K
1.25%
-23.74K
-2.40%
Mar 31, 2025
The Vanguard Group, Inc.
2.49M
3.23%
+39.55K
+1.61%
Mar 31, 2025
Adams Street Partners, LLC
3.28M
4.25%
--
--
Mar 31, 2025
RTW Investments L.P.
2.68M
3.47%
--
--
Mar 31, 2025
Miller (Richard A)
2.32M
3.01%
+559.07K
+31.66%
May 07, 2025
Vivo Capital, LLC
2.23M
2.9%
--
--
Mar 31, 2025
Foresite Capital Management, LLC
1.58M
2.05%
--
--
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
